TOPLINE: Nirsevimab implementation in Catalonia, Spain, was associated with a 44% reduction in emergency department (ED) visits for bronchiolitis in infants younger than 6 months and a 48% reduction in hospital admissions compared with previous seasons. The multinational study analyzed 1,574,392 ED visits and 255,689 hospital admissions across Spain, the United Kingdom, and Italy. METHODOLOGY: … Read more
A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the European level to protect infants in their first season of exposure to the virus) to infants can halve hospitalizations for bronchiolitis. It is the result of a study involving the Università Cattolica del … Read more
Chubut Province protects Infants with RSV Vaccine for Pregnant individuals Table of Contents Chubut Province protects Infants with RSV Vaccine for Pregnant individuals RSV Vaccine Linked to Fewer Hospitalizations Understanding RSV and the Vaccine Protecting Infants from RSV: A Q&A What is RSV and why is it critically important? What’s happening in Chubut Province regarding … Read more
TOPLINE: Among children with a history of severe bronchiolitis during infancy, low serum 25-hydroxyvitamin D (25(OH)D) levels ( METHODOLOGY: Researchers conducted a prospective study to examine the association between serum 25(OH)D levels at the age of 3 years and the risk for the onset of eosinophilic asthma by the age of 6 years among children … Read more